<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> are a heterogenous group of disorders characterized by abnormalities in the maturation and differentiation of hematopoietic cells </plain></SENT>
<SENT sid="1" pm="."><plain>A single diagnostic test is not available but laboratory and clinical features are often characteristic </plain></SENT>
<SENT sid="2" pm="."><plain>The French-American-British Co-operative Group has classified these disorders into five subgroups </plain></SENT>
<SENT sid="3" pm="."><plain>Despite distinctive morphologic features, this classification identifies only two major prognostic groups </plain></SENT>
<SENT sid="4" pm="."><plain>The natural history is variable with some patients rapidly developing <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>, others experiencing complications of <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> in the absence of <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>, while others have minimal symptoms and prolonged survivals </plain></SENT>
<SENT sid="5" pm="."><plain>A number of therapeutic modalities have been used including hematinics, steroids, <z:chebi fb="0" ids="26537">retinoids</z:chebi>, low-dose chemotherapy, aggressive chemotherapy, and bone marrow transplantation </plain></SENT>
<SENT sid="6" pm="."><plain>Supportive care is the mainstay of treatment for most patients </plain></SENT>
</text></document>